FDA regulatory application heralds a new contender in ankylosing spondylitis with AbbVie’s Rinvoq

abbvie
AbbVie is already conducting a Phase III study, SELECT Axis 2, examining the safety and efficacy of Rinvoq in patients with milder axSpA. Credit: Shutterstock.